The Daily Ledger

HealthNews

India Moves to Tighten Medicine Storage Rules From Warehouse to Pharmacy

The Union Health Ministry has proposed adding Good Storage and Distribution Practices to the Drugs Rules, 1945. The framework would set clearer expectations for procurement, storage, transport, records and traceability across the pharmaceutical supply chain.

The Daily Ledger Staff4 min read
A medicine supply chain from a temperature-controlled warehouse through refrigerated transport to a pharmacy, with quality checks and tracking.
Illustration generated with AI

The Union Ministry of Health and Family Welfare has proposed bringing Good Storage and Distribution Practices (GSDP) for pharmaceutical products into the Drugs Rules, 1945. Announced on 19 November, the proposal aims to strengthen oversight of medicines after they leave the manufacturing or import stage and as they move through warehouses, distributors, transport networks and other supply-chain channels before reaching patients.

The ministry says the framework is intended to preserve the quality, safety, efficacy and integrity of pharmaceutical products throughout distribution. It builds on guidance developed by the Central Drugs Standard Control Organisation (CDSCO) and would provide a more formal regulatory basis for practices covering procurement, purchasing, storage, distribution, transportation, documentation and record-keeping.

What the proposed practices cover

Good Storage and Distribution Practices focus on maintaining appropriate conditions for medicines beyond the factory gate. Pharmaceutical products can be exposed to risks while being stored or moved, including unsuitable temperatures or environmental conditions, contamination, mix-ups, falsification, diversion and unauthorised distribution. The proposed framework seeks to reduce these risks by setting expectations for how products are handled and tracked at each stage.

The ministry's announcement identifies a wide range of entities involved in the distribution chain. These include manufacturers, importers, wholesalers, distributors, stockists and other organisations responsible for moving or holding pharmaceutical products. The proposal emphasises documentation and traceability so that product identity and handling history can be followed through the supply chain.

Why storage and transport matter

Medicine quality is not determined only during manufacturing. Products must continue to be kept within their specified quality and environmental conditions during storage and transportation. If those conditions are not maintained, a product may deteriorate before it reaches the patient or healthcare provider. The risk is particularly relevant for products that require controlled storage conditions, although the exact requirements differ by product and its approved specifications.

Clear procedures can help organisations manage receiving, inspection, stock rotation, storage areas, transport arrangements, returns and records. Traceable documentation can also help identify where a product has travelled and which organisations handled it. The ministry says the proposed rules are intended to strengthen accountability across these activities rather than leave distribution practices solely to individual business procedures.

Role of drug regulators

If incorporated into the Drugs Rules, the GSDP requirements are expected to support regulatory oversight, inspection and enforcement by both the Central and State drug-control authorities. That could give regulators a more consistent framework for assessing how medicines are stored and distributed, while providing businesses with clearer expectations about compliance.

The proposal also connects to the wider work of the CDSCO, India's national regulatory authority for drugs and related products. The GSDP guidance developed by the organisation forms the basis of the proposed framework. The ministry's announcement does not describe a new medicine approval process; its focus is the quality-management and accountability systems used after products enter the distribution chain.

What happens next

The ministry has invited stakeholders and members of the public to submit objections and suggestions on the proposal. The announcement provides a postal address at Kartavya Bhawan-1 in New Delhi and an email contact for submissions to the Under Secretary (Drugs Regulation). The official Gazette notice is the relevant document for readers who want to examine the proposed legal text and consultation details.

Because the measure has been announced as a proposal, it should not be treated as an already implemented requirement. The final wording, any transition arrangements and the date on which amended provisions would take effect depend on the formal regulatory process. Pharmaceutical businesses and healthcare providers should refer to official ministry and CDSCO communications for the current position.

Why the proposal matters to patients

Patients generally encounter medicines at the pharmacy, clinic or hospital rather than seeing the storage and transport systems behind them. A stronger distribution framework is intended to help ensure that quality controls continue through those less visible stages. Better records and traceability may also help authorities and supply-chain operators investigate concerns when products are found to have been mishandled or diverted.

The proposal does not by itself guarantee that every medicine will be free from quality problems. Its significance lies in extending regulatory attention across the journey from manufacturer or importer to the point of supply. If adopted and effectively implemented, the framework could make responsibilities clearer and strengthen the systems that protect the integrity of medicines before they reach patients.

Sources

This story was prepared with the help of automated drafting tools and was reviewed and fact-checked by our editors before publication. See our Editorial Policy.

Report a problem with this story · Copyright & takedown